Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilizat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Commun Biol
Main Authors: Jørgensen, Astrid S., Daugvilaite, Viktorija, De Filippo, Katia, Berg, Christian, Mavri, Masa, Benned-Jensen, Tau, Juzenaite, Goda, Hjortø, Gertrud, Rankin, Sara, Våbenø, Jon, Rosenkilde, Mette M.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8115334/
https://ncbi.nlm.nih.gov/pubmed/33980979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-021-02070-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados